Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1

Interventions

Carboplatin 18Pemetrexed 10Paclitaxel 6pembrolizumab 5Nivolumab 5Cisplatin 5Gemcitabine 4osimertinib 3entinostat 3camrelizumab 3atezolizumab 3Erlotinib Hydrochloride 3selpercatinib 2pralsetinib 2durvalumab 2apatinib 2Vinorelbine 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Drug Delivery Systems 2Docetaxel 2Bronchoscopy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2zipalertinib 1zimberelimab 1toripalimab 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Diseases × ficlatuzumab × Thoracic × Clear all
NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

AVEO Pharmaceuticals, Inc.

Phase 1/2 Completed
203 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡